AttributesValues
type
value
  • Treatment options for severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta‐analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS‐CoV‐2. Primary outcome was all‐cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty‐nine studies with 5207 patients were included. Pooled all‐cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%‐17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97‐1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60‐9.45). There was no difference in other secondary outcomes. There is a need for well‐designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options.
Subject
  • Epidemiology
  • Emergency medicine
  • Evidence-based practices
  • Medical statistics
  • Primary alcohols
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software